Trial Profile
A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Grass/Rye Pollen Allergoid With MPL in Patients Sensitized to Grass and Rye Pollen.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2021
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary) ; Monophosphoryl lipid A
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Allergy Therapeutics
- 24 Nov 2006 New trial record.